• scottlissington

First New Zealand Registration of Guideline Recommended UTI Treatment

The Prescription Medicine UroFos® (fosfomycin) has been registered by Medsafe for the treatment of acute uncomplicated urinary tract infection (UTIs) in adult women and adolescents aged over 12.

"UroFos® represents the first of a new antibiotic class in New Zealand and is registered as a single dose treatment for women experiencing a UTI. Single dose oral fosfomycin is convenient and highly effective against a broad range of UTI causing bacteria, these advantages are reflected in PHARMACs high priority recommendation for funding.” Scott Lissington COO Te Arai BioFarma.

For more information:

UroFos® Data Sheet

Te Arai BioFarma Ltd. 0800 TE ARAI.

UroFos® (Fosfomycin) is a Prescription Medicine. For full information please consult the Medsafe website and product data sheet at UroFos® is a registered Trademark of Te Arai BioFarma Ltd, Auckland.

Te Arai BioFarma is a New Zealand owned family company created to improve access to Medicines for New Zealanders

3 views0 comments

Recent Posts

See All

MacroBID Dear Healthcare Professional Letter

Please find the "Dear Healthcare Professional Letter" containing additional information about the release characteristics and in-use shelf life of Macrobid® (nitrofurantoin macrocrystals/nitrofurantoi